Actinium Pharmaceuticals KOL Presentation: Discussing Positive Results from the Pivotal Phase 3 SIERRA Trial of Iomab-BKOL Event with Dr. Sergio Giralt
Efficacy and Safety Results of the Phase 3 SIERRA Trial of Iomab-B: 2023 TCT Tandem Meetings Late-Breaker Presentation
Lintuzumab-Ac225 in Combination with Intensive Chemotherapy Yields High Response Rate and MRD Negativity in R/R AML with Adverse Features
Early Clinical Evaluation of Potential Synergy of Targeted Radiotherapy with Lintuzumab-Ac225 and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia (AML)
Novel HER3 targeting antibody radioconjugates, 225Ac-HER3 ARC and 177Lu-HER3 ARC, exhibit potent antitumor efficacy in HER3-positive solid tumors
Targeting Myeloid-Derived Suppressor Cells with Actinium-225 Lintuzumab, a CD33 Antibody Radioconjugate to Enhance Antitumor Immunity
Clinical Experience in the Randomized Phase 3 SIERRA Trial: Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies
![Clinical Experience in the Randomized Phase 3 SIERRA Trial: Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies](https://d1io3yog0oux5.cloudfront.net/_8420da7cbf87722efee8d8004b7c961e/actiniumpharma/db/206/1024/pdf_thumbnail.jpg "Clinical Experience in the Randomized Phase 3 SIERRA Trial: Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies")